Current Role and Status for Intratumoral Injection Therapies in Metastatic Melanoma

Cancer J. 2024 Mar-Apr 01;30(2):108-112. doi: 10.1097/PPO.0000000000000709.ABSTRACTIntratumoral therapies represent a unique avenue for drug development in melanoma as patients often have accessible lesions that are particularly amenable to these approaches. In addition, a majority of intratumoral therapies have focused on stimulating antitumor immune responses, making them a particularly attractive option for use in melanoma. In this review, we describe applications for talimogene laherparepvec, a US Food and Drug Administration-approved intratumoral therapy in melanoma, as well as several classes of intratumoral therapies in development including novel oncolytic viruses, mRNA-based intratumoral injections, and cytokines and other signaling molecules.PMID:38527264 | DOI:10.1097/PPO.0000000000000709
Source: Cancer Journal - Category: Cancer & Oncology Authors: Source Type: research